Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2005
06/23/2005WO2005056540A1 Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia
06/23/2005WO2005056538A1 Oxazole derivatives of tetracyclines
06/23/2005WO2005056537A1 The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
06/23/2005WO2005056534A1 Reference standard for characterization of rosuvastatin
06/23/2005WO2005056527A1 Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
06/23/2005WO2005056525A2 Deacetylation of n-acetylglucosamine
06/23/2005WO2005056524A2 Therapeutic agents useful for treating pain
06/23/2005WO2005056523A2 Methodology for preparing combinatorial libraries based upon a bicyclic scaffold
06/23/2005WO2005056522A2 Indole compounds
06/23/2005WO2005056187A1 Phosphatase inhibitor sample collection system
06/23/2005WO2005056067A1 Silver coatings and methods of manufacture
06/23/2005WO2005056056A2 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
06/23/2005WO2005056048A1 Method for specifically increasing the sensitivity of tumor cells
06/23/2005WO2005056045A1 Methods and compositions related to plunc polypeptides
06/23/2005WO2005056043A2 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
06/23/2005WO2005056027A2 Solvent for biogenic active pharmaceutical ingredients
06/23/2005WO2005056024A1 Methods of enhancing stem cell engraftment
06/23/2005WO2005056023A1 Prebiotic combination products
06/23/2005WO2005056022A1 Enteropathy ameliorating composition
06/23/2005WO2005056021A1 Polynucleotides for reducing respiratory syncytial virus gene expression
06/23/2005WO2005056019A1 Remedy for malignant melanoma
06/23/2005WO2005056018A1 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
06/23/2005WO2005056017A1 Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
06/23/2005WO2005056016A1 Preventive and/or therapeutic agent for higher brain dysfunction
06/23/2005WO2005056015A1 Substituted piperazines
06/23/2005WO2005056014A1 Methods for suppressing an immune response or a treating a proliferative disorder
06/23/2005WO2005056012A1 Indole derivatives for the treatment of bone diseases
06/23/2005WO2005056011A1 Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
06/23/2005WO2005056010A1 Prevention and/or reduction of photoreceptor degeneration with retinoids
06/23/2005WO2005056009A1 Therapeutic agent for lung disease
06/23/2005WO2005056008A1 Intranasal compositions
06/23/2005WO2005056007A1 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person
06/23/2005WO2005056006A1 Use of chp as an inhibitor of glutathione s-transferases and collagen iv
06/23/2005WO2005056005A1 Chp-gemcitabin combined agent and use thereof as anti-tumoural active substances
06/23/2005WO2005056004A1 N-alkyl pyrroles as hmg-coa reductase inhibitors
06/23/2005WO2005056002A2 Use of inductors of the degradation pathway of gamma-butyrolactone for inactivating the homoserine lactone n-acyl signal of gram-negative pathogenic bacteria
06/23/2005WO2005056001A1 A use of khellactone derivatives and the composition comprising the same
06/23/2005WO2005056000A2 Neuroactive substance and uses of one such substance
06/23/2005WO2005055999A1 Anticholinergic agent
06/23/2005WO2005055998A1 Methods of treatment with lxr agonists
06/23/2005WO2005055997A1 Medicinal composition for treating and preventing inflammatory disease
06/23/2005WO2005055996A1 Memantine for the prevention or reduction of suicidality and for treatment of major depression associated with suicidality
06/23/2005WO2005055995A1 Terrein compound having melanin biosynthesis inhibitors and its preparation
06/23/2005WO2005055994A1 Treatment and preventions of asthma
06/23/2005WO2005055993A2 Pharmaceutical preparation containing gabapentin
06/23/2005WO2005055989A1 Drug-containing grains and solid preparation containing the grains
06/23/2005WO2005055983A2 Method of preparation of mixed phase co-crystals with active agents
06/23/2005WO2005055981A2 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
06/23/2005WO2005055975A2 Uv-stable semi-solid transdermal systems comprising a photosensitive active ingredient and a uv absorber
06/23/2005WO2005055973A2 Endoparasiticidal agents for topical application
06/23/2005WO2005055971A1 Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid
06/23/2005WO2005055963A2 Decontamination formulation with sorbent additive
06/23/2005WO2005055956A2 Method for improving insulin sensitivity by administering an inhibitor of antitrypsin
06/23/2005WO2005055955A2 DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
06/23/2005WO2005055953A2 Methods of preventing and treating gastrointestinal dysfunction
06/23/2005WO2005055952A2 Synergistic anti-cancer compositions
06/23/2005WO2005055951A2 Methods and compositions for slowing aging
06/23/2005WO2005055950A2 Glycopegylated factor ix
06/23/2005WO2005055947A2 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions
06/23/2005WO2005055945A2 Mucoadhesive drug delivery devices and methods of making and using thereof
06/23/2005WO2005055943A2 Vinorelbine derivatives
06/23/2005WO2005055941A2 Novel m3 muscarinic acetylcholine receptor antagonists
06/23/2005WO2005055940A2 Novel m3 muscarinic acetylcholine receptor antagonists
06/23/2005WO2005055939A2 Vinca derivatives
06/23/2005WO2005055935A2 Cationic substituted benzofurans as antimicrobial agents
06/23/2005WO2005055932A2 Therapeutic combinations and methods including irm compounds
06/23/2005WO2005055929A2 Methods and compositions for the treatment and management of hemoglobinopathy and anemia
06/23/2005WO2005055928A2 Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
06/23/2005WO2005055927A2 Compositions and methods for topical treatment of skin infection
06/23/2005WO2005055923A2 Method for treating athlete´s foot
06/23/2005WO2005055922A2 Use of benzothiopenes to treat and prevent prostate cancer
06/23/2005WO2005055921A2 Compositions for treatment of ear disorders and methods of use thereof
06/23/2005WO2005055739A1 Edible compositions which are adapted for use by a companion animal
06/23/2005WO2005055738A1 Dietary non-essential amino acid tyrosine regulates the body weight of animals through regulating the animal appetite or food intake
06/23/2005WO2005055720A1 Alkyl ethanolamines for the control of mycobacteria in functional fluid
06/23/2005WO2005046662A3 Hdl-boosting combination therapy complexes
06/23/2005WO2005046643A3 Method for drug loading in liposomes
06/23/2005WO2005042422A3 Optical fiber with low pmd and method of making it by spinning
06/23/2005WO2005042020A3 Combinations for hcv treatment
06/23/2005WO2005041977A3 Process for producing injectable gabapentin compositions
06/23/2005WO2005041919A3 Medicamentously targeted local lipolysis
06/23/2005WO2005041888A3 Pyrimidin-4-one compounds, compositions and methods
06/23/2005WO2005040156A8 Azole derivative useful as antifungal agents with reduced interaction with metabolic cytochromes
06/23/2005WO2005040129A3 Ccr3 receptor antagonists
06/23/2005WO2005040121A3 Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
06/23/2005WO2005039629A3 Caspase inhibitors as coating materiel for medical products for inhibiting restenosis
06/23/2005WO2005039574A8 Therapeutic agent for keratoconjunctive disorder
06/23/2005WO2005037784A3 Crystalline form of gamma-aminobutyric acid analog
06/23/2005WO2005037272A8 Benzimidazole derivatives and use thereof as peptide deformylase inhibitors
06/23/2005WO2005037224A3 Muscarinic acetylcholine receptor antagonists
06/23/2005WO2005034870A3 Amide compounds and ion channel ligands and uses thereof
06/23/2005WO2005033105A3 Vanilloid receptor ligands and their use in treatments
06/23/2005WO2005033056A3 Triphenylethylene compounds as selective estrogen receptor modulators
06/23/2005WO2005032485A3 Compounds and methods for the treatment of attention-deficit hyperactivity disorder
06/23/2005WO2005030333A3 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2] [2]- benzazepine, method for the production thereof and use thereof in the production of medicaments
06/23/2005WO2005030187A3 Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
06/23/2005WO2005027887A3 Methods and compositions for improving endothelial function
06/23/2005WO2005027873A3 Therapeutic aminoglycoside-containing hydrogel nanoparticles
06/23/2005WO2005025555A3 Combinations of an aryl aniline beta-2 adrenergic receptor agonist and a corticosteroid
06/23/2005WO2005025496A3 Aliphatic pyrazinoylguanidine sodium channel blockers
1 ... 4640 4641 4642 4643 4644 4645 4646 4647 4648 4649 4650 4651 4652 4653 4654 4655 4656 4657 4658 4659 4660 ... 7860